ClinicalTrials.gg
CompletedNCT01783886VIVID EASTUpdated May 12, 2016Results posted

Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement

A Phase 3 interventional study of Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) and Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) in Macular Edema, sponsored by Bayer. Completed at 25 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-12.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
381
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.

Enrollment
7th of 53
381 · median 49
Started
2013
with 2 others
Phase 3
11 of 53
none open now
Registered
9th of 53
by date
Lead sponsor
9 of 53
Bayer

Among the 53 studies testing aflibercept in Macular Edema, this one is the 7th largest by enrollment, is one of 3 that started in 2013, is one of 11 in phase 3, and was the 9th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing aflibercept in Macular Edema, or all of them as a file.
02

Study summary

To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular edema (DME) with central involvement.

03

Conditions studied

  • Macular Edema

Browse trials for

Keywords

  • Diabetic Macular Edema
  • DME
  • VEGF Trap-Eye
  • best-corrected visual acuity (BCVA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 18 years with type 1 or 2 diabetes mellitus
  • Subjects with diabetic macular edema (DME) secondary to diabetes mellitus involving the center of the macula in the study eye
  • Decrease in vision determined to be primarily the result of DME in the study eye
  • Best-corrected visual acuity (BCVA) early treatment diabetic retinopathy study (ETDRS) letter score of 73 to 24 (20/40 to 20/320) in the study eye

Exclusion criteria

Exclusion Criteria:

  • Laser photocoagulation (panretinal or macular) in the study eye within 90 days of Day 1
  • More than 2 previous macular laser treatments in the study eye
  • Previous use of intraocular or periocular in the study eye within 120 days of Day 1
  • Previous treatment with antiangiogenic drugs in either eye (pegaptanib sodium, bevacizumab, ranibizumab etc.) within 90 days of Day 1
  • Active proliferative diabetic retinopathy (PDR) in the study eye
  • Uncontrolled diabetes mellitus, as defined by >12%
  • Only 1 functional eye even if that eye is otherwise eligible for the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
381 participants (actual)

Study arms

  • Experimental
    Intravitreal Aflibercept Injection 2Q4

    Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF \[vascular endothelial growth factor\] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.

    Biological: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

  • Experimental
    Intravitreal Aflibercept Injection 2Q8

    Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.

    Biological: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

  • Active comparator
    Macular Laser Photocoagulation

    Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.

    Procedure: Macular Laser Photocoagulation

Interventions

  • Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).

  • Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).

  • ProcedureMacular Laser Photocoagulation

    Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)

    Visual function of the study eye was assessed using the ETDRS protocol, which is a widely accepted international standard for macular laser photocoagulation treatment. A higher score represents better functioning. LOCF censored measurements after additional treatment.

    Time frame: Baseline up to week 52

Secondary outcomes

  1. Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF

    Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.

    Time frame: Baseline up to week 52

  2. Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF

    Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.

    Time frame: Baseline up to week 52

  3. Percentage of Participants With a Greater Than Equal (>=) Two-step Improvement From Baseline in the ETDRS Diabetic Retinopathy Severity Score (DRSS) as Assessed by Fundus Photography (FP) at Week 52 - LOCF

    ETDRS DRSS: None (level 10); Mild to moderate nonproliferative diabetic retinopathy (DR) (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)

    Time frame: Baseline up to week 52

  4. Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF

    CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement.

    Time frame: Baseline up to week 52

  5. Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF

    The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.

    Time frame: Baseline up to week 52

  6. Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF

    The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.

    Time frame: Baseline up to week 52

07

Results

Posted Apr 5, 2016

Participant flow

The study was conducted at centers in China, Hong Kong, South Korea, and Russian Federation between 18 February 2013 (first participant first visit) and 09 March 2015 (last participant last visit) (data cut-off date).

Participant flow — Overall Study
MilestoneIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Macular Laser Photocoagulation
Started127127127
Participants received treatment127127124
Completed122116117
Not completed51110
Withdrew: Lost to follow-up030
Withdrew: Protocol deviation002
Withdrew: Withdrawal of consent by participant134
Withdrew: Adverse event454

Outcome measures

PrimaryChange From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)

Visual function of the study eye was assessed using the ETDRS protocol, which is a widely accepted international standard for macular laser photocoagulation treatment. A higher score represents better functioning. LOCF censored measurements after additional treatment.

Time frame:
Baseline up to week 52
Reported as:
Mean · Letters correctly read
Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)
Letters correctly readIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Macular Laser Photocoagulation
Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)13.7 ± 8.412.8 ± 9.5-0.2 ± 13.5
Statistical analysis
  • Intravitreal Aflibercept Injection 2Q4 vs Macular Laser Photocoagulation · ANCOVA · p = <0.0001 · Mean difference (final values): 14.1 · 97.5% CI 10.9 to 17.2Least Square (LS) mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser.
  • Intravitreal Aflibercept Injection 2Q8 vs Macular Laser Photocoagulation · ANCOVA · p = <0.0001 · Mean difference (final values): 13.6 · 97.5% CI 10.2 to 16.9LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser.
SecondaryPercentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF

Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.

Time frame:
Baseline up to week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF
Percentage of participantsIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Macular Laser Photocoagulation
Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF70.962.723.4
Statistical analysis
  • Intravitreal Aflibercept Injection 2Q4 vs Macular Laser Photocoagulation · Cochran-Mantel-Haenszel · p = <0.0001 · Cmh adjusted difference: 47.4 · 97.5% CI 35.0 to 59.9Cochran-Mantel-Haenszel (CMH). The estimate is calculated as EYLEA minus Laser.
  • Intravitreal Aflibercept Injection 2Q8 vs Macular Laser Photocoagulation · Cochran-Mantel-Haenszel · p = <0.0001 · Cmh adjusted difference: 39.2 · 97.5% CI 26.3 to 52.1The estimate is calculated as EYLEA minus Laser.
SecondaryPercentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF

Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.

Time frame:
Baseline up to week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF
Percentage of participantsIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Macular Laser Photocoagulation
Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF43.336.512.1
Statistical analysis
  • Intravitreal Aflibercept Injection 2Q4 vs Macular Laser Photocoagulation · Cochran-Mantel-Haenszel · p = <0.0001 · Cmh adjusted difference: 31.1 · 97.5% CI 19.2 to 43.0The estimate is calculated as EYLEA minus Laser.
  • Intravitreal Aflibercept Injection 2Q8 vs Macular Laser Photocoagulation · Cochran-Mantel-Haenszel · p = <0.0001 · Cmh adjusted difference: 24.3 · 97.5% CI 12.6 to 35.9The estimate is calculated as EYLEA minus Laser.
SecondaryPercentage of Participants With a Greater Than Equal (>=) Two-step Improvement From Baseline in the ETDRS Diabetic Retinopathy Severity Score (DRSS) as Assessed by Fundus Photography (FP) at Week 52 - LOCF

ETDRS DRSS: None (level 10); Mild to moderate nonproliferative diabetic retinopathy (DR) (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)

Time frame:
Baseline up to week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With a Greater Than Equal (>=) Two-step Improvement From Baseline in the ETDRS Diabetic Retinopathy Severity Score (DRSS) as Assessed by Fundus Photography (FP) at Week 52 - LOCF
Percentage of participantsIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Macular Laser Photocoagulation
Percentage of Participants With a Greater Than Equal (>=) Two-step Improvement From Baseline in the ETDRS Diabetic Retinopathy Severity Score (DRSS) as Assessed by Fundus Photography (FP) at Week 52 - LOCF60.762.321.7
Statistical analysis
  • Intravitreal Aflibercept Injection 2Q4 vs Macular Laser Photocoagulation · Cochran-Mantel-Haenszel · p = <0.0001 · Cmh adjusted difference: 39.1 · 97.5% CI 26.0 to 52.2The estimate is calculated as EYLEA minus Laser.
  • Intravitreal Aflibercept Injection 2Q8 vs Macular Laser Photocoagulation · Cochran-Mantel-Haenszel · p = <0.0001 · Cmh adjusted difference: 40.6 · 97.5% CI 27.6 to 53.7The estimate is calculated as EYLEA minus Laser.
SecondaryChange From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF

CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement.

Time frame:
Baseline up to week 52
Reported as:
Mean · micrometer
Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF
micrometerIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Macular Laser Photocoagulation
Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF-238.7 ± 172.5-234.7 ± 160.8-109.3 ± 206.9
Statistical analysis
  • Intravitreal Aflibercept Injection 2Q4 vs Macular Laser Photocoagulation · ANCOVA · p = <0.0001 · Median difference (final values): -130.5 · 97.5% CI -171.2 to -89.9LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser.
  • Intravitreal Aflibercept Injection 2Q8 vs Macular Laser Photocoagulation · ANCOVA · p = <0.0001 · Mean difference (final values): -131.4 · 97.5% CI -172.8 to -89.9LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser.
SecondaryChange From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF

The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.

Time frame:
Baseline up to week 52
Reported as:
Mean · Scores on a scale
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF
Scores on a scaleIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Macular Laser Photocoagulation
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF6.65 ± 23.867.28 ± 22.950.04 ± 24.39
Statistical analysis
  • Intravitreal Aflibercept Injection 2Q4 vs Macular Laser Photocoagulation · ANCOVA · p = 0.0364 · Mean difference (final values): 5.78 · 97.5% CI -0.41 to 11.97LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser.
  • Intravitreal Aflibercept Injection 2Q8 vs Macular Laser Photocoagulation · ANCOVA · p = 0.0113 · Mean difference (final values): 6.87 · 97.5% CI 0.80 to 12.94LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser.
SecondaryChange From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF

The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.

Time frame:
Baseline up to week 52
Reported as:
Mean · Scores on a scale
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF
Scores on a scaleIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Macular Laser Photocoagulation
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF3.93 ± 22.3610.25 ± 21.440.04 ± 23.14
Statistical analysis
  • Intravitreal Aflibercept Injection 2Q4 vs Macular Laser Photocoagulation · ANCOVA · p = 0.2688 · Mean difference (final values): 2.81 · 97.5% CI -2.90 to 8.53LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser.
  • Intravitreal Aflibercept Injection 2Q8 vs Macular Laser Photocoagulation · ANCOVA · p = 0.0009 · Mean difference (final values): 8.01 · 97.5% CI 2.64 to 13.37LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser.

Adverse events

Collected over From the start of study treatment up to 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intravitreal Aflibercept Injection 2Q4—19/127 (15%)87/127 (68.5%)
Intravitreal Aflibercept Injection 2Q8—22/127 (17.3%)83/127 (65.4%)
Macular Laser Photocoagulation—24/124 (19.4%)89/124 (71.8%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Macular Laser Photocoagulation
Vitreous haemorrhageEye disorders1/1270/1274/124
GlaucomaEye disorders0/1270/1272/124
Visual acuity reducedEye disorders0/1270/1272/124
HypoglycaemiaMetabolism and nutrition disorders1/1270/1272/124
Diabetic nephropathyRenal and urinary disorders0/1271/1272/124
CataractEye disorders2/1271/1270/124
Type 2 diabetes mellitusMetabolism and nutrition disorders0/1272/1271/124
Cerebral infarctionNervous system disorders2/1272/1270/124
Nephrogenic anaemiaBlood and lymphatic system disorders1/1270/1271/124
Acute myocardial infarctionCardiac disorders1/1270/1271/124
Most frequent other events
Showing 10 of 19
Most frequent other events
EventIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Macular Laser Photocoagulation
Visual acuity reducedEye disorders12/12714/12724/124
Conjunctival haemorrhageEye disorders18/12713/1276/124
Diabetic retinal oedemaEye disorders17/12713/12715/124
Retinal haemorrhageEye disorders14/12717/12712/124
Visual acuity tests abnormalInvestigations9/1273/12715/124
HypertensionVascular disorders10/12715/1278/124
Retinal aneurysmEye disorders9/12713/12710/124
Retinal exudatesEye disorders8/12713/1275/124
Diabetes mellitusMetabolism and nutrition disorders12/12710/12711/124
Macular oedemaEye disorders8/12710/1279/124

Baseline characteristics

Age, Continuous
Age, Continuous(years)Intravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Macular Laser PhotocoagulationTotal
Mean59.3 ± 10.357.6 ± 10.158.8 ± 10.558.5 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Intravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Macular Laser PhotocoagulationTotal
Female686060188
Male596764190
Region of Enrollment
Region of Enrollment(participants)Intravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Macular Laser PhotocoagulationTotal
China10110199301
Russia1010929
Other Asia-Pacific (Hong Kong, Korea)16161648
08

Study locations

25 sites
  • Guangzhou, Guangdong 510064, China
  • Wuhan, Hubei 430040, China
  • Changsha, Hunan 410011, China
  • Shenyang, Liaoning 110034, China
  • Xi'an, Shaanxi 710032, China
  • Qingdao, Shandong, China
  • Chengdu, Sichuan 610041, China
  • Hangzhou, Zhejiang 310009, China
  • Wenzhou, Zhejiang, China
  • Beijing, 100044, China
  • Beijing, 100050, China
  • Beijing, 100083, China
  • Beijing, 100730, China
  • Beijing, 2000080, China
  • Chongqing, 400042, China
  • Shanghai, China
  • Tianjin, China
  • Hong Kong, Hong Kong
  • Kowloon, Hong Kong
  • Seoul, 135-710, Korea, Republic of
  • Seoul, 138-736, Korea, Republic of
  • Moscow, 105062, Russian Federation
  • Moscow, 127486, Russian Federation
  • Novosibirsk, 630071, Russian Federation
  • St. Petersburg, 197022, Russian Federation
09

References and documents

Publications

  • Chen YX, Li XX, Yoon YH, Sun X, Astakhov Y, Xu G, Wang H, Ren X, Asmus F; VIVID-East investigators. Intravitreal Aflibercept versus Laser Photocoagulation in Asian Patients with Diabetic Macular Edema: The VIVID-East Study. Clin Ophthalmol. 2020 Mar 9;14:741-750. doi: 10.2147/OPTH.S235267. eCollection 2020. PubMed 32210527 ↗
  • Ming J, Zhang Y, Xu X, Zhao M, Wang Y, Chen Y, Zhang F, Wang J, Liu J, Zhao X, Han R, Hu S. Cost-effectiveness analysis of intravitreal aflibercept in the treatment of diabetic macular edema in China. J Comp Eff Res. 2020 Feb;9(3):161-175. doi: 10.2217/cer-2019-0174. Epub 2020 Jan 6. PubMed 31904267 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2013
First posted
Feb 5, 2013
Start
Feb 2013
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Apr 5, 2016
Last update
May 12, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01783886
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Feb 5, 2013
Start date
Feb 2013
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Apr 5, 2016
Last update
May 12, 2016

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion